Skip to main content

Work in progress

Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change. 


Open consultations

We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. 

We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.

Title: All Wales paediatric asthma management and prescribing guidelines

Status: Consultation open - available here

Remit: This document sets out the patient pathway for Wales, explicit in management options for each healthcare setting, referral thresholds, and national medication choices. It is a document aimed at supporting a national, standardised, safer and sustainable approach to asthma care in children.

Estimated publication date: March-May 2023

Title: All Wales Common Ailments Service formulary (update)

Status: Consultation open - available here

Remit: The Common Ailments Service aims to improve patient access to consistent, evidence-based advice for the management of common ailments. This document includes updated monographs for the 26 ailments covered by the Service.

Estimated publication date: March-May 2023

Back to top


Medicines appraisals

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Medicine name: sofosbuvir/velpatasvir (Epclusa®)

Reference number: 4573

Indication: Treatment of chronic hepatitis C (HCV) in patients from 3 years of age to less than 18 years of age

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

AWMSG meeting date: 08/02/2023

Medicine name: levodopa/carbidopa/entacapone (Lecigon®)

Reference number: 4871

Indication: Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 11/01/2023

AWMSG meeting date: 19/04/2023

Back to top


Medicines optimisation projects

Title: Polypharmacy review – guidance for prescribing (2022 update)

Status: Consultation completed

Remit: This will update and replace the existing ‘Polypharmacy: Guidance for prescribing’ document. The intention of this revision has been to focus the guidance on the groups of medicines commonly prescribed in the elderly population that may require review.

Estimated publication date: December 2022-February 2023

Title: Understanding unlicensed medicines

Status: Consultation completed

Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients.

Estimated publication date: March-May 2023

Title: All Wales paediatric asthma management and prescribing guidelines

Status: Consultation open - available here

Remit: This document sets out the patient pathway for Wales, explicit in management options for each healthcare setting, referral thresholds, and national medication choices. It is a document aimed at supporting a national, standardised, safer and sustainable approach to asthma care in children.

Estimated publication date: March-May 2023

Title: All Wales Common Ailments Service formulary (update)

Status: Consultation open - available here

Remit: The Common Ailments Service aims to improve patient access to consistent, evidence-based advice for the management of common ailments. This document includes updated monographs for the 26 ailments covered by the Service.

Estimated publication date: March-May 2023

Back to top


One Wales Medicine assessments

One Wales Medicine reassessment

Medicine name: rituximab

Reference number: OW12

Indication: Treatment of myasthenia gravis in adults.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 28/02/2023

OWMAG date: March 2023

One Wales Medicine new assessment

Medicine name: infliximab

Reference number: OW23

Indication: Treatment of pulmonary sarcoidosis refractory to standard treatments and when there are no pharmacological alternatives.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

One Wales Medicine new assessment

Medicine name: vedolizumab (Entyvio®)

Reference number: OW24

Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children. 

  • Crohn's disease: following loss of response or non-response to anti-TNF and ustekinumab;
  • ulcerative colitis: following loss of response or non-response to anti-TNF treatment.

Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

One Wales Medicine new assessment

Medicine name: ustekinumab (Stelara®)

Reference number: OW25

Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children. 

  • Crohn's disease: following loss of response or non-response to anti-TNF;
  • ulcerative colitis: following loss of response or non-response to anti-TNF and vedolizumab.

Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

Back to top


Policies, strategies and other publications

 

Title: AWMSG annual report 2022-2023

Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2021 and March 2022.

Estimated publication date: September 2023

View previous AWMSG annual reports

Title: IPFR annual report 2022-2023

Summary: Review of Individual Patient Funding Request activity in Wales between April 2021 and March 2022. 

Estimated publication date: September 2023

View previous IPFR annual reports

Back to top

Follow AWTTC: